bioAffinity Technologies Secures Australian Patent for Lung Disease Detection Platform

bioAffinity Technologies has announced the acceptance of an Australian patent application for its platform technology to detect and characterize multiple lung diseases. The patent application covers methods using flow cytometry to reveal disease-related changes across multiple cell types in a sputum sample. This innovation has the potential to lead to new diagnostic tools for personalized lung health. The Australian patent complements existing intellectual property protection in the US and other international jurisdictions, strengthening the company's global patent portfolio.